AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...
The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...
Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...
Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...
AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...
In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...
TORK US on MSN4d
This is how Audi was born: the origin of its iconic four ringsThis is the origin of the Audi logo, a symbol full of globalization, a design available to any mortal, easy to reproduce by ...
AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top ...
DelveInsight's ROS1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback